Literature DB >> 16474161

Virus and cell RNAs expressed during Epstein-Barr virus replication.

Jing Yuan1, Ellen Cahir-McFarland, Bo Zhao, Elliott Kieff.   

Abstract

Changes in Epstein-Barr virus (EBV) and cell RNA levels were assayed following immunoglobulin G (IgG) cross-linking-induced replication in latency 1-infected Akata Burkitt B lymphoblasts. EBV replication as assayed by membrane gp350 expression was approximately 5% before IgG cross-linking and increased to more than 50% 48 h after induction. Seventy-two hours after IgG cross-linking, gp350-positive cells excluded propidium iodide as well as gp350-negative cells. EBV RNA levels changed temporally in parallel with previously defined sensitivity to inhibitors of protein or viral DNA synthesis. BZLF1 immediate-early RNA levels doubled by 2 h and reached a peak at 4 h, whereas BMLF1 doubled by 4 h with a peak at 8 h, and BRLF1 doubled by 8 h with peak at 12 h. Early RNAs peaked at 8 to 12 h, and late RNAs peaked at 24 h. Hybridization to intergenic sequences resulted in evidence for new EBV RNAs. Surprisingly, latency III (LTIII) RNAs for LMP1, LMP2, EBNALP, EBNA2, EBNA3A, EBNA3C, and BARTs were detected at 8 to 12 h and reached maxima at 24 to 48 h. EBNA2 and LMP1 were at full LTIII levels by 48 h and localized to gp350-positive cells. Thus, LTIII expression is a characteristic of late EBV replication in both B lymphoblasts and epithelial cells in immune-comprised people (J. Webster-Cyriaque, J. Middeldorp, and N. Raab-Traub, J. Virol. 74:7610-7618, 2000). EBV replication significantly altered levels of 401 Akata cell RNAs, of which 122 RNAs changed twofold or more relative to uninfected Akata cells. Mitogen-activated protein kinase levels were significantly affected. Late expression of LTIII was associated with induction of NF-kappaB responsive genes including IkappaBalpha and A20. The exclusion of propidium, expression of EBV LTIII RNAs and proteins, and up-regulation of specific cell RNAs are indicative of vital cell function late in EBV replication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474161      PMCID: PMC1395376          DOI: 10.1128/JVI.80.5.2548-2565.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  105 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript.

Authors:  G C Perng; C Jones; J Ciacci-Zanella; M Stone; G Henderson; A Yukht; S M Slanina; F M Hofman; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  Science       Date:  2000-02-25       Impact factor: 47.728

Review 3.  DNA methylation and the Epstein-Barr virus.

Authors:  R F Ambinder; K D Robertson; Q Tao
Journal:  Semin Cancer Biol       Date:  1999-10       Impact factor: 15.707

4.  Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival.

Authors:  W E Hobbs; D E Brough; I Kovesdi; N A DeLuca
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell.

Authors:  G J Babcock; D Hochberg; A D Thorley-Lawson
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

6.  Global analysis of herpes simplex virus type 1 transcription using an oligonucleotide-based DNA microarray.

Authors:  S W Stingley; J J Ramirez; S A Aguilar; K Simmen; R M Sandri-Goldin; P Ghazal; E K Wagner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections.

Authors:  J Webster-Cyriaque; J Middeldorp; N Raab-Traub
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells.

Authors:  E D Cahir-McFarland; D M Davidson; S L Schauer; J Duong; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 9.  Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB.

Authors:  E D Cahir McFarland; K M Izumi; G Mosialos
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

10.  Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors.

Authors:  G J Babcock; D A Thorley-Lawson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

View more
  93 in total

1.  Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.

Authors:  Nirojini Sivachandran; Xueqi Wang; Lori Frappier
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

2.  Epstein-Barr virus BPLF1 deubiquitinates PCNA and attenuates polymerase η recruitment to DNA damage sites.

Authors:  Christopher B Whitehurst; Cyrus Vaziri; Julia Shackelford; Joseph S Pagano
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

Review 3.  The role of microRNAs in Epstein-Barr virus latency and lytic reactivation.

Authors:  Eleonora Forte; Micah A Luftig
Journal:  Microbes Infect       Date:  2011-07-28       Impact factor: 2.700

4.  Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication.

Authors:  Li Xing; Elliott Kieff
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

5.  Epstein-Barr virus thymidine kinase is a centrosomal resident precisely localized to the periphery of centrioles.

Authors:  Michael B Gill; Jeffery L Kutok; Joyce D Fingeroth
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

6.  IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3.

Authors:  Yoon-Jae Song; Kenneth M Izumi; Nicholas P Shinners; Benjamin E Gewurz; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-18       Impact factor: 11.205

7.  Global bidirectional transcription of the Epstein-Barr virus genome during reactivation.

Authors:  Tina O'Grady; Subing Cao; Michael J Strong; Monica Concha; Xia Wang; Sandra Splinter Bondurant; Marie Adams; Melody Baddoo; Sudesh K Srivastav; Zhen Lin; Claire Fewell; Qinyan Yin; Erik K Flemington
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

8.  The Translesion Polymerase Pol η Is Required for Efficient Epstein-Barr Virus Infectivity and Is Regulated by the Viral Deubiquitinating Enzyme BPLF1.

Authors:  Ossie F Dyson; Joseph S Pagano; Christopher B Whitehurst
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

9.  A Genome-Wide Epstein-Barr Virus Polyadenylation Map and Its Antisense RNA to EBNA.

Authors:  Vladimir Majerciak; Wenjing Yang; Jing Zheng; Jun Zhu; Zhi-Ming Zheng
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 10.  An Epigenetic Journey: Epstein-Barr Virus Transcribes Chromatinized and Subsequently Unchromatinized Templates during Its Lytic Cycle.

Authors:  Adityarup Chakravorty; Bill Sugden; Eric C Johannsen
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.